ArticleFrontiers in oncology2026
Case Report: Pelvic-perineal deep angiomyxoma presenting as hematoma-like paravaginal masses: a report of two cases.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deep angiomyxoma (DAM) is a rare, locally infiltrative mesenchymal tumor of the female pelvic and perineal regions that is often misdiagnosed because of nonspecific clinical and ultrasonographic findings. We report two cases of pelvic-perineal DAM initially interpreted as paravaginal hematomas. One patient underwent ultrasound-guided aspiration and thrombin injection before progressive enlargement prompted further evaluation. Magnetic resonance imaging (MRI) demonstrated marked T2 hyperintensity, internal swirling structures, and extension along pelvic floor tissue planes, raising suspicion of DAM. Both patients underwent surgical resection with histologically negative margins (R0). Histopathology confirmed DAM with estrogen receptor and progesterone receptor positivity. Following multidisciplinary discussion, both patients received six cycles of individualized postoperative gonadotropin-releasing hormone agonist therapy. No radiological recurrence was observed at 11 and 12 months, respectively. Persistent or enlarging hematoma-like pelvic-perineal masses without a clear precipitating factor should prompt consideration of DAM and further MRI evaluation. MRI is useful for suggesting DAM and delineating tumor extent, whereas definitive diagnosis relies on histopathology. The benefit of routine postoperative endocrine therapy after R0 resection remains uncertain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.